When Diamyd presented its quarterly report last week, Ulf Hannelius said the company was at “a decisive stage in the development of retogatein.” This was because the interim analysis of efficacy data from the DIAGNODE‑3 study — which evaluates the treatment in individuals recently diagnosed with type 1 diabetes — was approaching.
Disappointment for Diamyd in Phase III – the share price plunges
Diamyd Medical’s share was sharply down on Monday following negative Phase III results. “This outcome is highly unexpected,” said the company’s CEO, Ulf Hannelius.
Advertisement
BREAKING